The ING gene family in the regulation of cell growth and tumorigenesis

Journal of Cellular Physiology

Volumn 218, Issue 1, 2009, Pages 45-57

  Coles, Andrew H ^a   Jones, Stephen N ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; GROWTH INHIBITOR; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIM ING4; PROTEIN ING1; PROTEIN ING2; PROTEIN ING3; PROTEIN ING5; PROTEIN P53; UNCLASSIFIED DRUG; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPAIR; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ANGIOGENESIS; ANIMAL; CELL MOTION; CHEMISTRY; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOME; MOUSE; NEOPLASM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION; GENOME; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MULTIGENE FAMILY; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 58149171661     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21583     Document Type: Review

References (144)

1. Aasland R, Gibson TJ, Stewart AF. 1995. The PHD finger: Implications for chromatinmediated transcriptional regulation. Trends Biochem Sci 20:56-59.
2. Avvakumov N, Cote J. 2007. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26:5395-5407.
3. Aylon Y, Oren M. 2007. Living with p53, dying of p53. Cell 130:597-600.
4. Berardi P, Russell M,El-Osta A, Riabowol K. 2004. Functional links between transcription, DNA repair and apoptosis. Cell Mol Life Sci 61:2173-2180.
5. Berra E, Ginouves A, Pouyssegur J. 2006. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 7:41-45.
6. Bienz M. 2006. The PHD finger, a nuclear protein-interaction domain. Trends Biochem Sci 31:35-40.
7. Binda O, Nassif C, Branton PE. 2008. SIRTI negatively regulates HDACI-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 27:3384-3392.
8. Bottomley MJ,Stier G,Pennacchini D,Legube G,Simon B,Akhtar A,Sattler M,Musco G. 2005. NMR structure of the first PHD finger of autoimmune regulator protein (AIREI). Insights into autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy (APECED) disease. J Biol Chem 280:II505-II5I2.
9. Campos EI,Cheung KJ, Jr.,Murray A, Li S, Li G. 2002. The noveltumoursuppressor gene INGI is overexpressed in human melanoma cell lines. Br J Dermatol I46:574-580.
10. Campos EI, Chin MY, Kuo WH, Li G. 2004a. Biological functions of the ING family tumor suppressors. Cell Mol Life Sci 6I:2597-26I3.
11. Campos EI, Martinka M, Mitchell DL, Dai DL, Li G. 2004b. Mutations of the INGI tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair. Int J Oncol 25:73-80.
12. Cengiz B, Gunduz M, Nagatsuka H, Beder L, Gunduz E, Tamamura R, Mahmut N, Fukushima K, Ali MA, Naomoto Y, Shimizu K, Nagai N. 2007. Fine deletion mapping of chromosome 2q2I-37shows three preferentially deleted regions in oral cancer. Oral Oncol 43:24I-247.
13. Chen L, Matsubara N,Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y, Naomoto Y, Isozaki H, Riabowol K, Tanaka N. 200I. Genetic alterations of candidate tumor suppressor INGI in human esophagealsquamous cell cancer. Cancer Res 6I:4345-4349.
14. Chen B, Campos EI, Crawford R, Martinka M, Li G. 2003. Analyses of the tumour suppressor INGI expression and gene mutation in human basal cell carcinoma. Int J Oncol 22:927-93I.
15. Chen LS, Wei JB, Zhou YC, Zhang S, Liang JL, Cao YF, Tang ZJ, Zhang XL, Gao F. 2005. Genetic alterations and expression ofinhibitor ofgrowth I in human sporadic colorectal cancer. World J Gastroenterol II:6I20-6I24.
16. Cheung KJ,Jr.,Li G.200I.The tumor suppressor INGI: Structure and function. Exp Cell Res 268:I-6.
17. Cheung KJ, Jr., Li G. 2002. The tumour suppressor p33INGI does not enhance camptothecin-induced cell death in melanoma cells. Int J Oncol 20:I3I9-I322.
18. Cheung KJ, Jr., Bush JA, Jia W, Li G. 2000. Expression of the novel tumour suppressor p33(INGI)is independent ofp53. Br J Cancer 83:I468-I472.
19. Cheung KJ, Jr., Mitchell D, Lin P, Li G. 200I. The tumor suppressor candidate p33(INGI) mediates repair of UV-damaged DNA. Cancer Res 6I:4974-4977.
20. Chin MY,Ng KC,Li G.2005.The novel tumor suppressor p33ING2 enhances UVB-induced apoptosis in human melanoma cells. Exp Cell Res 304:53I-543.
21. Coles AH, Liang H, Zhu Z, Marfella CG, Kang J, Imbalzano AN,Jones SN. 2007. Deletion of p37IngI in mice reveals a p53-independent role for IngI in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res 67:2054-206I.
22. Colla S,Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A,Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N.2007. The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro- angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)- I{alpha} activity being involved in myeloma-induced angiogenesis. Blood II0:4464-4475.
23. Contzler R, Regamey A, Favre B, Roger T, Hohl D, Huber M. 2006. Histone acetyltransferase HBOI inhibits NF-kappaB activity by coactivator sequestration. Biochem Biophys Res Commun 350:208-2I3.
24. Denslow SA, Wade PA. 2007. The human Mi-2/NuRD complex and gene regulation. Oncogene 26:5433-5438.
25. Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, Lane WS, Tan S, Yang XJ, Cote J. 2006. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2I:5I-64.
26. Fegers I,Kob R,Eckey M,Schmidt O,Goeman F,Papaioannou M,Escher N,von Eggeling F, Melle C,Baniahmad A.2007.The tumor suppressors p33INGI and p33ING2 interactwith alien in vivo and enhance alien-mediated gene silencing. J Proteome Res 6:4I82-4I88.
27. Feng X, Hara Y, Riabowol K. 2002. Different HATS of the INGI gene family. Trends Cell Biol I2:532-538.
28. Feng X, Bonni S, Riabowol K. 2006. HSP70 induction by ING proteins sensitizes cells to tumor necrosis factor alpha receptor-mediated apoptosis. Mol Cell Biol 26:9244-9255.
29. Garate M, Campos EI, Bush JA, Xiao H, Li G. 2007. Phosphorylation of the tumor suppressor p33(INGIb) at Ser-I26 influences its protein stability and proliferation of
30. melanoma cells. FASEB J 2I:3705-37I6.
31. Garkavtsev I, Boucher Y. 2005. An intact INGI-P53 pathway can potentiate the cytotoxic effects of taxol. Cancer Biol Ther 4:48-49.
32. Garkavtsev I, Riabowol K. I997. Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33INGI candidate tumor suppressor. Mol Cell Biol I7:20I4-20I9.
33. Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. I996a. Suppression of the novel growth inhibitor p33INGI promotes neoplastic transformation. Nat Genet I4:4I5-420.
34. Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. I996b. Suppression of the novel growth inhibitor p33INGI promotes neoplastic transformation [Erratum appears in Nat Genet I999 Nov. 23: 373]. Nat Genet I4:4I5-420.
35. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV. I998a. The candidate tumour suppressor p33INGI cooperates with p53 in cell growth control. Nature 39I:295-298.
36. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV. I998b. The candidate tumour suppressor p33INGI cooperates with p53 in cell growth control [see comment]. Nature 39I:295-298.
37. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH, Jain RK. 2004. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428:328-332.
38. Goeman F, Thormeyer D, Abad M, Serrano M, Schmidt O, Palmero I, Baniahmad A. 2005. Growth inhibition by the tumor suppressor p33INGI in immortalized and primary cells: Involvement of two silencing domains and effect of Ras. Mol Cell Biol 25:422-43I.
39. Gong W, Suzuki K, Russell M, Riabowol K. 2005. Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol 37:I054-I065.
40. Gong W, Russell M, Suzuki K, Riabowol K. 2006. Subcellular targeting of p33INGIb by phosphorylation-dependentI4-3-3bindingregulates p2IWAFI expression. Mol Cell Biol 26:2947-2954.
41. Gonzalez L, Freije JM, Cal S, Lopez-Otin C, Serrano M, Palmero I. 2006. A functional link between the tumour suppressors ARF and p33INGI. Oncogene 25:5I73-5I79.
42. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, Confalonieri S, Cesaroni M, Marchesi F, Gasco M, Scanziani E, Capra M, Mai S, Nuciforo P, Crook T, Lough J, Amati B. 2007. Tip60 is ahaplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448:I063-I067.
43. Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR, Brugge JS, Ferguson CG, Payrastre B, Myszka DG, Cantley LC, Wagner G, Divecha N, Prestwich GD, Yuan J. 2003.The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell II4:99-III.
44. Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S, Nishizaki K, Shimizu K. 2000. Genomic structure of the human INGI gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 60:3I43-3I46.
45. Gunduz M, Ouchida M, Fukushima K, Ito S,Jitsumori Y, Nakashima T, Nagai N, Nishizaki K, Shimizu K. 2002. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q3I, in human head and neck cancers. Oncogene 2I:4462-4470.
46. Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, Ouchida M, Tsujigiwa H, Yamachika E, Fukushima K, Beder L, Hirohata S, Ninomiya Y, Nishizaki K, Shimizu K, Nagai N. 2005. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor geneat I2pI3, in head and neck squamous cell carcinomas. Gene 356:I09-II7.
47. Gunduz M, Beder LB, Gunduz E, Nagatsuka H, Fukushima K, Pehlivan D, Cetin E, Yamanaka N, Nishizaki K, Shimizu K, Nagai N. 2007. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci 99:53I-538.
48. Ha S, Park S, Yun CH, Choi Y. 2002. Characterization of nuclear localization signal in mouse INGI homolog protein. Biochem Biophys Res Commun 293:I63-I66.
49. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell I00:57-70.
50. Harris SL, Levine AJ. 2005. The p53 pathway: Positive and negative feedback loops. Oncogene 24:2899-2908.
51. He GH, Helbing CC, Wagner MJ, Sensen CW,Riabowol K.2005. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol 22:I04-II6.
52. Helbing CC,Veillette C, Riabowol K, Johnston RN, Garkavtsev I. I997. A novel candidate tumor suppressor, INGI, is involved in the regulation of apoptosis. Cancer Res 57:I255-I258.
53. Iizuka M, Sarmento OF, Sekiya T, Scrable H, Allis CD, Smith MM. 2007. HboI links p53- dependent stress signaling to DNA replication licensing. Mol Cell Biol 28:I40-I53.
54. Ito K, Kinjo K, Nakazato T, Ikeda Y, Kizaki M. 2002. Expression and sequence analyses of p33(INGI) gene in myeloid leukemia. Am J Hematol 69:I4I-I43.
55. Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S, Takami Y, Kinoshita M, Yokomise H. 2003. Reduced INGIb gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. Clin Cancer Res 9:4926-4934.
56. Kataoka H, Bonnefin P,Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC, Riabowol K. 2003. INGI represses transcription by direct DNA binding and through effects on p53. Cancer Res 63:5785-5792.
57. Kichina JV, Zeremski M, Aris L, Gurova KV, Walker E, Franks R, Nikitin AY, Kiyokawa H, Gudkov AV. 2006. Targeted disruption of the mouse ing I locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 25:857-866.
58. Kim S. 2005. HuntING4 new tumor suppressors. Cell Cycle 4:5I6-5I7.
59. Kim S, Chin K, Gray JW, Bishop JM.2004. A screen for genes that suppress loss of contact inhibition: Identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA I0I:I625I-I6256.
60. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S,Yokota J, Harris CC. 2008.Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2and up-regulatemir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68:3I93-3203.
61. Kuo WH, Wang Y, Wong RP, Campos EI, Li G. 2007. The INGIb tumor suppressor facilitates nucleotide excision repair by promoting chromatin accessibility to XPA. Exp Cell Res 3I3:I628-I638.
62. Kuzmichev A, Zhang Y, Erdjument-Bromage H, Tempst P, Reinberg D. 2002. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(INGI). Mol Cell Biol 22:835-848.
63. Laherty CD, Billin AN, Lavinsky RM, Yochum GS, Bush AC, Sun JM, Mullen TM, Davie JR, Rose DW, Glass CK, Rosenfeld MG, Ayer DE, Eisenman RN. I998. SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell 2:33-42.
64. Lan F, Collins RE, DeCegli R, Alpatov R, Horton JR, Shi X, Gozani O, Cheng X, Shi Y.2007. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSDI-mediated gene repression. Nature 448:7I8-722.
65. Leung KM, Po LS, Tsang FC, Siu WY, Lau A, Ho HT, Poon RY. 2002. The candidate tumor suppressor INGIb can stabilizep53 by disrupting there gulation of p53 by MDM2. Cancer Res 62:4890-4893.
66. Li J, Martinka M, Li G. 2008. Role of ING4 in human melanoma cell migration, invasion, and patient survival. Carcinogenesis 29:I373-I379.
67. Lu F, Dai DL, Martinka M, Ho V, Li G. 2006. Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer 95:80-86.
68. Malhotra V, Wong HR.2002.Interactionsbetween the heat shock response and the nuclear factor-kappaB signaling pathway. Crit Care Med 30:S89-S95.
69. Mourskaia AA, Northey JJ, Siegel PM. 2007. Targeting aberrant TGF-beta signalingin pre-clinical models of cancer. Anticancer Agents Med Chem 7:504-5I4.
70. Moynagh PN. 2005a. The NF-kappaB pathway. J Cell Sci 118:4589-4592.
71. Moynagh PN. 2005b. TLR signalling and activation of IRFs: Revisiting old friends from the NF- kappaB pathway. Trends Immunol 26:469-476.
72. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K, Harris CC. 2001. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA 98:9671-9676.
73. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC. 2003. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 22:343-350.
74. Neumann M, Naumann M. 2007. Beyond IkappaBs: Alternative regulation of NF-kappaB activity. FASEB J 21:2642-2654.
75. Nouman GS, Anderson JJ, Wood KM, Lunec J, Hall AG, Reid MM, Angus B. 2002a. Loss of nuclear expression of the p33(INGIb) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 55:596-601.
76. Nouman GS, Angus B, Lunec J, Crosier S, Lodge A, Anderson JJ. 2002b. Comparative assessment expression of the inhibitor of growth I gene (INGI) in normal and neoplastic tissues. Hybrid Hybridomics 2I:I-I0.
77. Nouman GS, Anderson JJ, Crosier S, Shrimankar J, Lunec J, Angus B. 2003a. Downregulation of nuclear expression of the p33(INGIb) inhibitor of growth protein in invasive carcinoma of the breast. J Clin Pathol 56:507-5II.
78. Nouman GS, Anderson JJ, Lunec J, Angus B. 2003b. The role of the tumour suppressor p33 INGIb in human neoplasia. J Clin Pathol 56:49I-496.
79. Ohgi T, Masaki T, Nakai S, Morishita A, Yukimasa S, Nagai M, Miyauchi Y, Funaki T, Kurokohchi K, Watanabe S, Kuriyama S. 2002. Expression of p33(INGI) in hepatocellular carcinoma: Relationships to tumour differentiation and cyclin E kinase activity. Scand J Gastroenterol 37:I440-I448.
80. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S. 2006. Alterations in novel candidate tumor suppressor genes, INGI and ING2 in human lung cancer. Oncol Rep I5:545-549.
81. Ozer A, Wu LC, Bruick RK. 2005. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci USA I02:748I-7486.
82. Pascual J, Martinez-Yamout M, Dyson HJ, Wright PE. 2000. Structure of the PHD zinc finger from human Williams-Beuren syndrome transcription factor. J Mol Biol 304:723-729.
83. Pedeux R,Sengupta S, Shen JC, Demidov ON, Saito S,Onogi H, Kumamoto K, Wincovitch S, Garfield SH, McMenamin M, Nagashima M, Grossman SR, Appella E, Harris CC. 2005. ING2 regulates the onset of replicative senescence by induction ofp300-dependent p53 acetylation. Mol Cell Biol 25:6639-6648.
84. Pena PV, Davrazou F, Shi X, Walter KL,Verkhusha VV, Gozani O, Zhao R, Kutateladze TG. 2006. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442:I00-I03.
85. Pena PV, Hom RA, Hung T, Lin H, Kuo AJ, Wong RP, Subach OM, Champagne KS, Zhao R, Verkhusha VV, Li G, Gozani O, Kutateladze TG. 2008. Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of INGI tumor suppressor. J Mol Biol 380:303-3I2.
86. Perkins ND. 2004. NF-kappaB: Tumor promoter or suppressor? Trends Cell Biol 14:64-69.
87. Ponder BA. 200I. Cancer genetics. Nature 4II:336-34I.
88. Ragvin A, Valvatne H, Erdal S, Arskog V, Tufteland KR, Breen K, Oyah AM, Eberharter A, Gibson TJ, Becker PB, Aasland R. 2004. Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. J Mol Biol 337:773-788.
89. Ran R, Lu A,Zhang L, Tang Y, Zhu H, Xu H, Feng Y, Han C, Zhou G, Rigby AC, Sharp FR. 2004. Hsp70 promotes TNF-mediated apoptosis by binding IKK gamma and impairing NF-kappa B survival signaling. Genes Dev I8:I466-I48I.
90. Rayet B, Gelinas C. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene I8:6938-6947.
91. Ripperger T, von Neuhoff N, Kamphues K, Emura M, Lehmann U, Tauscher M, Schraders M,Groenen P, Skawran B, Rudolph C, Callet-Bauchu E, van Krieken JH, Schlegelberger B, Steinemann D. 2007. Promoter methylation of PARGI, a novel candidate tumor suppressor gene in mantle-cell lymphomas. Haematologica 92:460-468.
92. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, Straatman H, Larizza L, Schoen makers EF. 2006. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 25:I57I-I583.
93. Sager R. I997. Expression genetics in cancer: Shifting the focus from DNA to RNA. Proc Natl Acad Sci USA 94:952-955.
94. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. 2003. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol I63:505-5I6.
95. Sarker KP, Kataoka H,Chan A,Netherton SJ, Pot I, Huynh MA, Feng X, Bonni A, Riabowol K, Bonni S. 2008. ING2as a novel mediator of TGF-beta-dependent responses in epithelial cells. J Biol Chem 283:I3269-I3279.
96. Schraders M, Pfundt R, Straatman HM, Janssen IM, van Kessel AG, Schoenmakers EF, van Krieken JH, Groenen PJ. 2005. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood I05:I686-I693.
97. Scott M, Boisvert FM, Vieyra D, Johnston RN, Bazett-Jones DP, Riabowol K. 200Ia. UV induces nucleolar translocation of INGI through two distinct nucleolar targeting sequences. Nucleic Acids Res 29:2052-2058.
98. Scott M, Bonnefin P, Vieyra D, Boisvert FM, Young D, Bazett-Jones DP, Riabowol K. 2001b. UV-induced binding of INGI to PCNA regulates the induction of apoptosis. J Cell Sci II4:3455-3462.
99. Serra-Pages C, Kedersha NL, Fazikas L, Medley Q, Debant A, Streuli M. 1995. The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J I4:2827-2838.
100. Shen DH, Chan KY, Khoo US, Ngan HY, Xue WC, Chiu PM, Ip P, Cheung AN. 2005. Epigenetic and genetic alterations of p33INGIb in ovarian cancer. Carcinogenesis 26:855-863.
101. Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC. 2007. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alphaI. Cancer Res 67:2552-2558.
102. Sherr CJ. I998. Tumor surveillance via the ARF-p53 pathway. Genes Dev I2:2984-299I.
103. Sherr CJ. 2006. Divorcing ARF and p53: An unsettled case. Nat Rev Cancer 6:663-673.
104. Sherr CJ, Weber JD. 2000. The ARF/p53 pathway. Curr Opin Genet Dev I0:94-99.
105. Shi X, Gozani O. 2005. The fellowships of the INGs. J Cell Biochem 96:II27-II36.
106. Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T, Carney D, Pena P, Lan F, Kaadige MR, Lacoste N, Cayrou C, Davrazou F, Saha A, Cairns BR, Ayer DE, Kutateladze TG, Shi Y, Cote J, Chua KF, Gozani O. 2006a. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442:96-99.
107. Shi Y, Tu Z, Tang D, Zhang H, Liu M, Wang K, Calderwood SK, Xiao X. 2006b. The inhibition of LPS-induced production of inflammatory cytokines by HSP70 involves inactivation of the NF-kappaB pathway but not the MAPK pathways. Shock 26:277-284.
108. Shimada Y, Saito A, Suzuki M, Takahashi E, Horie M. I998.Cloningofanovel gene (INGIL) homologous to INGI, a candidate tumor suppressor. Cytogenet Cell Genet 83:232-235.
109. Shimada H, Liu TL, Ochiai T, Shimizu T, Haupt Y, Hamada H, Abe T,Oka M, Takiguchi M, Hiwasa T. 2002. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression ofp33(INGI) in T.Tn human esophageal carcinoma cells. Oncogene 2I:I208-I2I6.
110. Shinoura N, Muramatsu Y, Nishimura M, Yoshida Y, Saito A, Yokoyama T, Furukawa T, Horii A, Hashimoto M, Asai A, Kirino T, Hamada H. I999. Adenovirus-mediated transfer of p33INGI with p53 drastically augments apoptosis in gliomas. Cancer Res 59:552I-5528.
111. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC. 2003. p29ING4 and p28ING5 bind top53 and p300, and enhance p53 activity. Cancer Res 63:2373-2378.
112. Silverstein RA, Ekwall K. 2005. Sin3: A flexible regulator of global gene expression and genome stability. Curr Genet 47:I-I7.
113. Skowyra D, Zeremski M, Neznanov N, Li M, Choi Y, Uesugi M, Hauser CA, Gu W, Gudkov AV, Qin J. 200I. Differential association of products of alternative transcripts of the candidate tumor suppressor INGI with the mSin3/HDACI transcriptional corepressor complex. J Biol Chem 276:8734-8739.
114. Soliman MA, Riabowol K. 2007. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 32:509-5I9.
115. Stark M, Puig-Butille JA, Walker G, Badenas C, Malvehy J, Hayward N, Puig S. 2006. Mutation of the tumour suppressor p33INGIb is rare in melanoma. Br J Dermatol I55:94-99.
116. Takahashi M, Seki N, Ozaki T, Kato M, Kuno T, Nakagawa T, Watanabe K, Miyazaki K, Ohira M, Hayashi S, Hosoda M, Tokita H, Mizuguchi H, Hayakawa T, Todo S, Nakagawara A. 2002. Identification of the p33(INGI)-regulated genes that include cyclin BI and proto-oncogene DEK by using cDNA microarrayin a mouse mammary epithelial cell line NMuMG. Cancer Res 62:2203-2209.
117. Tallen G, Riabowol K, Wolff JE. 2003. Expression of p33INGI mRNA and chemosensitivity in brain tumor cells. Anticancer Res 23:I63I-I635.
118. Tallen G, Kaiser I, Krabbe S, Lass U, Hartmann C, Henze G, Riabowol K, von Deimling A. 2004. No INGI mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Int J Cancer I09:476-479.
119. Tallen UG,Truss M, Kunitz F, Wellmann S, Unryn B, Sinn B, Lass U, Krabbe S, Holtkamp N, Hagemeier C, Wurm R, Henze G, Riabowol KT, von Deimling A.2007. Down-regulation of the inhibitor of growth I (INGI) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol 86:23-30.
120. Thomas T, Voss AK. 2007. The diverse biological roles of MYST histone acetyltransferase family proteins. Cell Cycle 6:696-704.
121. Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S, Sugimachi K. 2000. Diminished expression of INGI mRNA and the correlation with p53 expression in breast cancers. Cancer Lett I52:I5-22.
122. Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K. I999. Suppression of INGI expression in sporadic breast cancer. Oncogene I8:5I87-5I93.
123. Tsang FC, Po LS, Leung KM, Lau A, Siu WY, Poon RY. 2003. INGIb decreases cell proliferation through p53-dependent and -independent mechanisms. FEBS Lett 553:277-285.
124. Unoki M, Shen JC, Zheng ZM, Harris CC. 2006. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 28I:34677-34686.
125. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. I996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274:787-789.
126. Vieyra D, Loewith R, Scott M, Bonnefin P, Boisvert FM, Cheema P, Pastyryeva S, Meijer M, Johnston RN, Bazett-Jones DP, McMahon S, Cole MD, Young D, Riabowol K. 2002a. Human INGI proteins differentially regulate histone acetylation. J Biol Chem 277:29832-29839.
127. Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K. 2002b. INGI isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res 62:4445-4452.
128. Vieyra D, Senger DL, Toyama T, Muzik H, Brasher PM, Johnston RN, Riabowol K, Forsyth PA. 2003. Altered subcellular localization and low frequency of mutations of INGI in human brain tumors. Clin Cancer Res 9:5952-596I.
129. Walzak AA, Veldhoen N, Feng X, Riabowol K, Helbing CC. 2007. Expression profiles of mRNA transcript variants encoding the human inhibitor of growth tumor suppressor gene family in normal and neoplastic tissues. Exp Cell Res. 3I4:273-285.
130. Wang Y, Li G. 2006. ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J Biol Chem 28I:II887-II893.
131. Wang J, Chin MY, Li G. 2006a. The novel tumor suppressor p33ING2 enhances nucleotide excision repair via inducement of histone H4 acetylation and chromatin relaxation. Cancer Res 66:I906-I9II.
132. Wang Y, Wang J, Li G. 2006b. Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett 580:3787-3793.
133. Wang Y, Dai DL, Martinka M, Li G. 2007. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res I3:4III-4II6.
134. Wijnhoven SW, Hoogervorst EM, de Waard H, van der Horst GT, van Steeg H. 2007. Tissue specific mutagenic and carcinogenic responses in NER defective mouse models. Mutat Res 6I4:77-94.
135. Xin H, Yoon HG, Singh PB, Wong J, Qin J. 2004. Components of a pathway maintaining histone modification and heterochromatin protein I binding at the pericentric heterochromatin in Mammalian cells. J Biol Chem 279:9539-9546.
136. Yu GZ, Zhu MH, Zhu Z, Ni CR, Zheng JM, Li FM. 2004. Genetic alterations and reduced expression of tumor suppressor p33(INGIb) in human exocrine pancreatic carcinoma. World J Gastroenterol I0:3597-360I.
137. Zeremski M, Hill JE, Kwek SS, Grigorian IA, Gurova KV, Garkavtsev IV, Diatchenko L, Koonin EV, Gudkov AV. I999. Structure and regulation of the mouse ingI gene. Three alternative transcripts encode two PHD finger proteins that have opposite effects on p53 function. J Biol Chem 274:32I72-32I8I.
138. Zhang X, Xu LS, Wang ZQ, Wang KS, Li N, Cheng ZH, Huang SZ, Wei DZ, Han ZG. 2004. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett 570:7-I2.
139. Zhang X, Wang KS, Wang ZQ, Xu LS, Wang QW, Chen F, Wei DZ, Han ZG. 2005. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem Biophys Res Commun 33I:I032-I038.
140. Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC. 2007. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett 26I:I83-I92.
141. Zhang JT, Wang DW, Li QX, Zhu ZL, Wang MW, Cui DS, Yang YH, Gu YX, Sun XF. 2008. Nuclear to cytoplasmic shift of p33(INGIb) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables. J Cancer Res Clin Oncol I34:42I-426.
142. Zhu JJ, Li FB, Zhou JM, Liu ZC, Zhu XF, Liao WM. 2005a. The tumor suppressor p33INGIb enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells. Cancer Biol Ther 4:39-47.
143. Zhu Z, Lin J, Qu JH, Feitelson MA, Ni CR, Li FM, Zhu MH. 2005b. Inhibitory effect of tumor suppressor p33(INGIb) and its synergy with p53 gene in hepatocellular carcinoma. World J Gastroenterol II:I903-I909.
144. Zhu JJ, Li FB, Zhu XF, Liao WM. 2006. The p33INGIb tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sci 78:I469-I477.